MDY vs XBI
SPDR S&P MidCap 400 ETF Trust vs SPDR S&P Biotech ETF
- • MDY has the lower expense ratio at 0.23% vs 0.35% for XBI.
- • MDY pays a higher dividend yield (1.05%).
Side-by-side metrics
| Metric | MDY | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.23% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.05% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $25.95B | $10.92B |
YTD return | 13.32% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.98 | 1.01 |
P/E ratio | 20.15 | — |
Last price | $681.87 | $156.41 |
Inception | — | — |
Issuer | State Street | State Street |
MDY top holdings
| TWLO | Twilio Inc Class A | 1.33% |
| OKTA | Okta Inc Class A | 1.03% |
| FTI | TechnipFMC PLC | 0.79% |
| NVT | nVent Electric PLC | 0.77% |
| ATI | ATI Inc | 0.76% |
| ENTG | Entegris Inc | 0.69% |
| UTHR | United Therapeutics Corp | 0.69% |
| XPO | XPO Inc | 0.61% |
| THC | Tenet Healthcare Corp | 0.61% |
| SNX | TD Synnex Corp | 0.61% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About MDY
MDY (SPDR S&P MidCap 400 ETF Trust) is Tracks the S&P MidCap 400 index. Managed by State Street, the fund carries $25.9B in assets under management, an expense ratio of 0.23%, a dividend yield of 1.05%. Its largest holding is Twilio Inc Class A (TWLO), which represents 1.3% of the portfolio. Real Estate is the fund's largest sector exposure at 7.8%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.